AVITA Medical, Inc. (ASX: AVH) — Two Catalysts, Twelve Days, a Doubled Share Price
Written by Christopher Hall, AdvDipFP | Authorised Representative, AFSL 526688 | August 2026
AVITA Medical, Inc. (ASX: AVH) — Two Catalysts, Twelve Days, a Doubled Share Price
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) is a US-domiciled, commercial-stage regenerative medicine company in wound care, built around RECELL — its autologous cell-harvesting device, or "spray-on skin" — alongside a broadening commercial portfolio in Cohealyx and PermeaDerm. AVH has now held a spot in the FMP Top 10 across four consecutive weekly readings, entering on 13 August 2026 off the back of its Q2 CY2026 result and extending the run on a follow-up clinical and economic study released 18 August. In the twelve days between those two announcements, AVH's ASX share price rose from A$1.28 to A$2.71 — up 111.7%.
Why AVH Appeared in the FMP Top 10
AVH first entered the FMP Top 10 on 13 August 2026, at a +89.17% quarterly gain. It has held a Top 10 position across four consecutive weekly readings since. In the dataset captured Friday 28 August 2026 (pre-close — see data note below), AVH held:
Two dated announcements sit behind the run. On 6 August 2026, AVH released its Q2 CY2026 financial and business update: net revenue of US$21.7 million, up 18% year on year and 13% quarter on quarter — a record quarter — with gross margin of 81.9% and full-year 2026 revenue guidance raised to US$86–89 million. The company guided to cash flow breakeven in Q4 2026, supported by a US$10 million Tranche B facility available once trailing 12-month net revenue reaches US$85 million. On 18 August 2026, AVITA announced positive results from its randomized controlled PermeaDerm-I clinical study: PermeaDerm, a biosynthetic wound matrix, delivered clinically comparable outcomes to cadaveric allograft while reducing product cost by 70% — a mean treatment cost of US$148.70 per 1% total body surface area treated, against US$497.10 for allograft (p<0.001), alongside a 95.7% reduction in preparation time.
AVH's ASX Share Price Over the Run
AVH's ASX-quoted share price, in Australian dollars, moved in three distinct gaps rather than one smooth climb. It gapped from A$1.17 to A$1.335 on 1–2 July 2026 (+14.1%) — a move with no ASX announcement identified in the documents reviewed this session. It gapped again from A$1.28 on 6 August 2026 (the day of the Q2 result) to A$1.54 the following session (+20.3%) and on to A$2.03 by 10 August (a further +31.8%). It gapped a third time from A$2.20 on 18 August (the day of the PermeaDerm announcement) to A$2.71 by 19 August (+23.2%) — a cumulative gain of 111.7% across the second and third gaps alone, over twelve days. All company financial figures in this article are reported in US dollars, as disclosed by AVITA Medical; the share price figures above are AVH's ASX-quoted price in Australian dollars and are not converted between the two currencies.
What Pattern Did AVH Show on the ASX Chart?
AVH's move is not one episodic pivot — it is a sequence of at least three separate ones, each its own gap. The first, on 1–2 July 2026, has no catalyst identified in the announcements reviewed this session. The second, running 6–10 August, is tied to the Q2 CY2026 result. The third, on 18–19 August, is tied to the PermeaDerm-I study. Rather than fading between gaps, each successive pivot held its ground and built on the last — that stacking is what has kept AVH inside the FMP Top 10 across four consecutive weekly readings, rather than a single isolated spike.
Mark Minervini's framing of what separates a gap that holds from one that fails applies to each of AVH's three pivots in turn: "The better that you are at reading supply and demand, the more accurate you're going to be in determining whether a breakout that pops out and comes back is one that's going to work, versus one that's just going to fail." A record revenue quarter, raised guidance and a statistically significant clinical readout (p<0.001) are the kind of supply-and-demand evidence behind the second and third gaps; the first remains unexplained by any source reviewed this session.
Traders wanting the full mechanics of this pattern can read FMP's the news-gap episodic pivot framework.
About AVITA Medical and Its Core Business
AVITA Medical's commercial platform centres on RECELL, FDA-approved for thermal burn and full-thickness skin defect treatment in the US, and also CE-marked in Europe, TGA-certified in Australia, Medsafe-listed in New Zealand and PMDA-approved in Japan. The Company's broader portfolio includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix — both distributed under exclusive US rights. In its Q1 CY2026 briefing, AVITA reported a 10-year BARDA agreement worth up to US$25.5 million (US$3.8 million guaranteed) for US burn preparedness, and RECELL GO clearance in Australia and New Zealand. RECELL GO — the Company's automated cell-processing system — recorded its first documented UK clinical use in June 2026, a 17-patient case series at Stoke Mandeville Hospital presented at the British Burn Association Annual Meeting, reporting complete graft take and no complications.
Cary Vance, President and CEO, said of the PermeaDerm-I results: "By combining comparable clinical performance with meaningful economic value and a simpler workflow, we believe PermeaDerm addresses an important need for hospitals while strengthening AVITA's differentiated acute wound care portfolio."
Key Metrics at Time of Coverage
Metric | Value |
Date first appeared in FMP Top 10 | 13 August 2026 |
Quarterly gain at entry | +89.17% |
Quarterly gain (current capture) | +139.83% |
Days on FMP Top 30 at publication | 40 |
FMP Launch Pad entry | 44 trading sessions before this capture |
Gain since FMP Launch Pad entry | +146.09% |
Sector classification | US-domiciled commercial-stage wound care and regenerative medicine company |
Data source | FMP Momentum Research, weekly Top 10 momentum dataset, captured Friday 28 August 2026 pre-close |
Data note — read this before the figures. This dataset was captured on Friday 28 August 2026 before the market closed. The prices behind every percentage above are therefore intraday, not closing prices, and will differ from Friday's close. The ranking, the thematic composition and the day counters are unaffected by that timing; the individual percentages should be read as accurate to the moment of capture rather than to a settled session. AVH's own A$1.28–A$2.71 price points (6–19 August) are settled closing prices cited separately from this dataset.
Thematic Context
AVH sits inside the healthcare thematic — specifically medical devices, given RECELL is a point-of-care autologous cell-harvesting device rather than a small-molecule drug. It is also tagged for its US revenue exposure as a US-domiciled operating company. AVH's run has coincided with a broader run of healthcare names inside the FMP Top 10 across recent weeks. For the full weekly board AVH is currently appearing on, see the FMP Top 10 momentum rankings.
Frequently Asked Questions
What does AVITA Medical do?
AVITA Medical is a US-domiciled, commercial-stage regenerative medicine company in wound care, built around RECELL — an FDA-approved autologous cell-harvesting device — alongside Cohealyx and PermeaDerm, dual-listed on the ASX (AVH) and NASDAQ (RCEL).
Why is AVH in the FMP Top 10?
AVH entered the FMP Top 10 on 13 August 2026 following its 6 August Q2 CY2026 result — record revenue, raised guidance and a path to Q4 2026 cash flow breakeven — and has extended its run following a second catalyst, the 18 August PermeaDerm-I clinical study results.
What pattern did AVH show on the ASX chart?
AVH shows a sequence of at least three separate episodic pivots — dated gaps on 1–2 July (catalyst not identified), 6–10 August (the Q2 result) and 18–19 August (the PermeaDerm-I study) — each holding its ground and building on the last, rather than one single pivot or a smooth continuation.
How much has AVH's ASX share price moved since its Q2 result?
AVH's ASX-quoted share price rose from A$1.28 on 6 August 2026 to A$2.71 by 19 August 2026 — a gain of 111.7% across the twelve days spanning its Q2 result and the PermeaDerm study announcement.
What is PermeaDerm and why does the study matter?
PermeaDerm is AVITA Medical's biosynthetic wound matrix. Its PermeaDerm-I randomized controlled study, released 18 August 2026, showed clinically comparable outcomes to cadaveric allograft while reducing product cost by 70% and preparation time by 95.7%.
How can I track AVH on the ASX?
AVH's weekly FMP Top 10 appearances, quarterly gain and Launch Pad history are tracked on the FMP Top 10 momentum rankings, updated weekly from FMP's proprietary momentum research.
Remember that past performance is no guarantee of future results, and all trading involves risk.
Access the Full FMP Momentum Research
FMP members access the weekly Top 30 ASX momentum data — the same proprietary research that tracked AVH's run across four consecutive Top 10 readings — 19 hours before the Gary Glover weekly session goes live. This article draws on that research for educational context on AVH's momentum profile. Join the FMP YouTube Membership for full access.
Sources
# | Source | Type |
1 | FMP Momentum Research, weekly Top 10 momentum dataset, captured Friday 28 August 2026 pre-close | Analyst Note |
2 | AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), "Second Quarter 2026 Financial and Business Update", 6 August 2026 | ASX Announcement |
3 | AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), "AVITA Medical Announces Positive PermeaDerm Study Results", 18 August 2026 | ASX Announcement |
4 | AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), "First Quarter 2026 Briefing", May 2026 | ASX Announcement |
5 | AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), "AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting", 18 June 2026 | ASX Announcement |
All percentage figures drawn from the FMP momentum dataset derive from a capture on Friday 28 August 2026 and are not closing-price figures. AVH's A$1.28–A$2.71 share price points (6–19 August 2026) are settled ASX closing prices, cited separately from that dataset. All AVITA Medical company financial figures are reported in US dollars as disclosed by the company.
Related Finer Market Points Educational Resources
Educational Disclaimer: This content is for educational purposes only and does not constitute financial advice. Past performance is no guarantee of future results. Consider your financial situation and seek professional advice before making investment decisions.
Finer Market Points Pty Ltd, CAR 1304002, AFSL 526688, ABN 87 645 284 680. This general information is educational only and not financial advice, recommendation, forecast or solicitation. Consider your objectives, financial situation and needs before acting. Seek appropriate professional advice. We accept no liability for any loss or damages arising from use. Authors and presenters may hold positions in discussed companies and investment products.
Comments